Although treatment with epoetin-alfa (EPO) and newer erythrocyte stimulating agents (ESA) has mitigated its severity, some recent studies have reported adverse outcomes of effective anemia correction with EPO and other ESAs [1-3]. The gene discussed is EPO; the disease is anemia (phenotype).